ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 IIT in refractory B-cell acute lymphoblastic leukemia. Further, its pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, NaPi2b, and ASCT2. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

Period	PE Ratio
2020-12-31	-0.29
2021-12-31	-0.36
2022-12-31	-0.55
2023-12-31	-0.37
2024-12-31	-0.67
2025-12-31	-0.97

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ADCT	$1.09	-1.80%	1.73M
3
4
5

ADC Therapeutics SA (ADCT) PE Ratio

PE Ratio Data

Get ADC Therapeutics SA Data in Excel

More ADCT Financial Data